Author Question: What is the primary advantage of using monoclonal antibodies (MABs) rather than polyclonal ... (Read 64 times)

rl · **on:** Jul 23, 2018

What is the primary advantage of using monoclonal antibodies (MABs) rather than polyclonal antibodies?

1. Oral administration
2. Single dosing
3. Broad-spectrum use
4. Fewer side effects

Question 2

The nurse preparing to administer the initial dose of an immunosuppressant agent for a client recovering from organ transplantation would make certain that screening has been performed to rule out:

1. electrolyte imbalance.
2. cardiomegaly.
3. anemia.
4. infectious processes.

soda0602 · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

Correct Answer: 4
Rationale 1: Monoclonal antibodies are administered intravenously.
Rationale 2: Monoclonal antibodies require multiple dosing.
Rationale 3: Monoclonal antibodies have a narrow spectrum of use.
Rationale 4: Fewer adverse effects are the primary advantage of MABs.
Global Rationale: Because a single B cell produces a single antibody, it is called a monoclonal antibody (MAB). A MAB is very specific, targeting a single type of target cell or receptor. This allows greater effects on the target cell or receptor at lower doses and with fewer adverse effects than using polyclonal antibodies. These drugs are administered intravenously, require multiple dosing, and have a narrow spectrum of use.

Answer to Question 2

Correct Answer: 4
Rationale 1: An electrolyte balance would not be an indication to withhold an immunosuppressant.
Rationale 2: Cardiomegaly would not need to be ruled out prior to administration of an immunosuppressant.
Rationale 3: The client with anemia could benefit from an immunosuppressant, especially if the client has hemolytic anemia.
Rationale 4: The priority would be to rule out infectious processes because administration of an immunosuppressant could exacerbate an infection.
Global Rationale: Prior to the initiation of immunosuppressant therapy, it is critical that the patient be carefully assessed to rule out active infections. This includes screening for viruses such as cytomegalovirus (CMV), hepatitis B and C viruses, Epstein-Barr virus (EBV), VZV, HIV, and herpes simplex virus (HSV). Electrolyte imbalance, cardiomegaly, and anemia do not need to be ruled out prior to this therapy.